Dr. Garg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 3rd Street
Cambridge, MA 02142Phone+1 617-732-5500
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1993 - 1996- University of California San Francisco School of MedicineClass of 1993
Publications & Presentations
PubMed
- 223 citationsEffects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D. Solomon, David Adams, Arnt V. Kristen, Martha Grogan, Alejandra González-Duarte
Circulation. 2019-01-22 - 133 citationsHormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysisPushkal P Garg, Karla Kerlikowske, Leslee L. Subak, Deborah Grady
Obstetrics and Gynecology. 1998-09-01 - 184 citationsEffect of the ownership of dialysis facilities on patients' survival and referral for transplantation.Pushkal P. Garg, Kevin D. Frick, Marie Diener-West, Neil R. Powe
The New England Journal of Medicine. 1999-11-25
Press Mentions
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with CardiomyopathySeptember 8th, 2022- Patisiran Meets Primary Endpoint in Trial for ATTR Amyloidosis, CardiomyopathyAugust 4th, 2022
- Alnylam's Stock Jumps 57% After Sharing Positive News for Its Experimental RNAi TherapyAugust 3rd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
